ANTI-TUMOR IMMUNE RESPONSE ENHANCER
Application
US20260085286A1
Kind: A1
Mar 26, 2026
Assignee
Kenichiro HASUMI
Inventors
Kenichiro HASUMI, Ko RII
Abstract
The present invention aims to provide means to maintain and enhance the anti-tumor activity of TADC in a tumor microenvironment. The present inventors found that when a composition comprising three kinds of phospholipids “cPLs adjuvant” is administered, the degree of growth of tumors implanted to mice was notably suppressed, and confirmed that immature dendritic cells, when cultured in vitro in the presence of the cPLs adjuvant, become mature bone marrow-derived dendritic cells and induce cytokine production.
CPC Classifications
C12N 5/0639
C12N 2501/999
Filing Date
2023-08-28
Application No.
19110297